Single center study with low enrollment

This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.

Inclusion Criteria:

• Willing and able to provide written informed consent
• Peripheral capillary oxygen saturation (SpO2) ≥ 95% on room air at screening
• Age ≥18 years

Exclusion Criteria:

• Hospitalized or impending hospitalization at the time of screening
• Symptoms of cough, fever or shortness of breath within 72 hours
• Prior or current treatment with other experimental or approved agents targeting SARS-CoV-2 or SARS-CoV-1
• Positive pregnancy test
• Active autoimmune disease or sarcoidosis (with the exception of controlled thyroid disease)
• Active decompensated liver disease (ascites, encephalopathy)
• Active congestive heart failure

Adverse event data were collected from the time of informed consent through protocol Day 28

Single-blinded study